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Background: Dilated cardiomyopathy (DCM) is the most common heart disease in Doberman Pinschers.
MicroRNAs (miRNAs) are short non-coding RNAs playing important roles in gene regulation. Different miRNA
expression patterns have been described for DCM in humans and might represent potential diagnostic markers.
There are no studies investigating miRNA expression profiles in canine DCM. The aims of this study were to screen
the miRNA expression profile of canine serum using miRNA microarray and to compare expression patterns of a
group of Doberman Pinschers with DCM and healthy controls.
Results: Eight Doberman Pinschers were examined by echocardiography and 24-hour-ECG and classified as healthy
(n = 4) or suffering from DCM (n = 4). Total RNA was extracted from serum and hybridized on a custom-designed
8x60k miRNA microarray (Agilent) containing probes for 1368 individual miRNAs. Although total RNA concentrations
were very low in serum samples, 404 different miRNAs were detectable with sufficient signal intensity on miRNA
microarray. 22 miRNAs were differentially expressed in the two groups (p < 0.05 and fold change (FC) > 1.5), but
did not reach statistical significance after multiple testing correction (false discovery rate adjusted p > 0.05). Five
miRNAs were selected for further analysis using quantitative Real-Time RT-PCR (qPCR) assays. No significant
differences were found using specific miRNA qPCR assays (p > 0.05).
Conclusions: Numerous miRNAs can be detected in canine serum. Between healthy and DCM dogs, miRNA
expression changes could be detected, but the results did not reach statistical significance most probably due to
the small group size. miRNAs are potential new circulating biomarkers in veterinary medicine and should be
investigated in larger patient groups and additional canine diseases.
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Dilated cardiomyopathy (DCM) is the most common
acquired heart disease in large- and giant-breed dogs.
DCM in dogs is therefore an important cause of cardiac
morbidity and death [1-3]. Doberman Pinschers are
among the most frequently affected breeds. DCM in
Doberman Pinschers is inherited and typically shows a
unique disease progression with a late onset [1,4-8].
Most dogs with clinical signs of heart disease were diag-
nosed at an age of 5 to 10 years [9]. Doberman Pinschers
at an age of 6 to 8 years showed a prevalence of 43.6%* Correspondence: gwess@lmu.de
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distribution, and reproduction in any mediumand older dogs a prevalence of 44.1%. Even if disease man-
ifests itself with an increasing age, younger Doberman
Pinschers are also affected. The cumulative prevalence of
DCM in Doberman Pinschers in Europe was demon-
strated to be 58.2% [8].
The natural progression of DCM can be characterized
by three stages [1,6,9-11]. Stage I is defined by a mor-
phologically and electrically normal heart. There is no
evidence of clinical signs of heart disease in this phase.
None of the currently available diagnostic tests can iden-
tify this stage. In the second stage (also called “occult
stage”), morphologic and/or electrical derangement is
presented in the absence of clinical signs of cardiac dis-
ease. Dogs typically appear absolutely normal to their
owners, despite evidence of abnormalities detectable byentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tricular enlargement and occurrence of ventricular pre-
mature contractions (VPCs). Morphological and electrical
abnormalities may coexist or be of predominantly one
form at the time of occult stage [1,12-15]. The diagnosis
of stage II consists of echocardiographic evaluation of left
ventricular dimensions and function and 24-hour ambula-
tory electrocardiogram (Holter monitoring) evaluating evi-
dence of ventricular arrhythmias. The DCM in Doberman
Pinschers usually starts with VPCs, which can lead to sud-
den cardiac death in about one third of the dogs. Later
morphological changes typical for DCM develop, which
can be detected by echocardiography. Stage III, the overt
stage, is characterized by the presence of clinical signs of
heart failure [1,12-15]. For prognostic and therapeutic but
also for breeding purposes, it is essential to diagnose
DCM before clinical signs develop.
Board-certified cardiologists recommend yearly screen-
ing of Doberman Pinschers for DCM by echocardiography
and Holter examination, starting at two years of age [4,8].
The combination of echocardiography and Holter moni-
toring are considered to be the gold standard for the
diagnosis of DCM in Doberman Pinschers. But both diag-
nostic methods have several disadvantages, including high
financial costs for the owners, the need for specialized
equipment and veterinary training, therefore limited avail-
ability and high interobserver variability [16]. The use of
circulating biomarkers in the diagnostic approach would
offer an attractive alternative because of widespread avail-
ability, quantitative nature, potential cost efficiency and
minimally invasive sample collection [16]. Therefore vari-
ous neurohormones and myocardial enzymes as biomar-
kers of DCM were evaluated [16-20].
MicroRNAs (miRNAs) are short (18 – 25 nucleotide
in length) non-coding RNAs which play important roles
in post-transcriptional gene regulation. miRNAs regulate
gene expression by binding to the 3′-untranslated region
of their target mRNA and consequently attenuating pro-
tein translation. miRNAs are involved in multiple bio-
logical processes [21,22]. It is estimated that more than
60% of human genes are fine-tuned by miRNAs [23].
Multiple studies investigated the potential benefit of
circulating miRNAs as noninvasive biomarkers and
discovered a remarkable stability of miRNAs in blood
[24-26]. The levels of miRNAs in serum are stable, re-
producible, and consistent among individuals of the
same species [26]. Endogenous circulating miRNAs are
stably expressed in human serum, whereas synthetic
miRNAs are immediately degraded [24]. However, the
exact mechanism how miRNAs enter into the serum
and how they are protected from enzymeatic degrad-
ation is still unknown [27].
A specific circulating miRNA expression pattern has
been described for various pathological conditions. It ispresumed that changes in the circulating miRNA expres-
sion pattern represent fingerprints for various diseases
[28-30] and may even precede detectable changes of stand-
ard diagnostic tools [28,31]. Several studies in humans
reported circulating miRNAs to be promising biomarkers
for cancer [24,30,32,33] and liver injury [28,34].
Various studies evaluated differences of miRNA expres-
sion in heart diseases. Several miRNAs were found to be
highly enriched in the heart [35-37]. miRNAs were shown
to be involved in cardiac development, myocyte growth
and arrhythmias following myocardial ischemia [38-43].
Experiments in mice have shown that gain or loss of func-
tion of individual miRNAs may elicit different forms of
heart disease. Cardiac overexpression of miR-195 in trans-
genic mice initially induced pathological cardiac growth
with disorganization of cardiomyocytes and progressed to
an echocardiographically confirmed dilated phenotype at
the age of six month that finally resulted in heart failure
[44]. Inhibition of miRNA biogenesis revealed DCM,
premature lethargy and heart failure in mice [45,46]. Liu
et al. demonstrated the essential role of miR-133a in the
cardiomyocyte proliferation: miR-133a-1 and miR-133a-2
double-mutant mice developed early large septal defects
that led to perinatal death, whereas mice that survived to
adulthood succumbed to DCM and heart failure. About
50% of surviving mice died from sudden death [47]. Find-
ings of these studies support the assumption that specific
miRNAs play an essential role in the control of cardiac
growth and remodeling leading to a dilated phenotype of
the heart. In 2007, Ikeda et al. detected different miRNA
expression patterns in human heart samples from control
patients and patients with DCM, aortic stenosis and ische-
mic cardiomyopathy (ICM). Eight miRNAs were differen-
tially expressed in ICM and DCM which indicates that
each form of heart disease is characterized by a specific
miRNA expression profile. Among other miRNAs, let-7c,
miR-21, miR-92 and miR-101 were deregulated in DCM
diseased tissue in contrast to healthy controls [48]. Later
experiments demonstrated miRNA expression differences
in heart failure either caused by idiopathic or ischemic
DCM and confirmed the aberrant expression of miR-92 in
DCM [49]. Levels of miR-208, miR-208b and miR-499
were higher in human endomyocardial samples of DCM
patients than in controls. Deregulation of individual
miRNA expression was associated with a poor clinical
outcome and therefore represents a potential prognostic
marker of human DCM [37,50]. Satoh et al. found a sig-
nificant difference in the expression of miR-21 in DCM
diseased tissue as well [50]. An increased risk of DCM
was also found in people with genetic polymorphisms in
the pre-stages of miR-196a and miR-499 [51]. In humans
with chronic heart failure caused by nonischemic DCM,
miR-142-3p was found to be upregulated in peripheral
blood cells [52].
Table 1 Baseline and clinical characteristics of study
population in the control and DCM diseased group
Control (n = 4) DCM (n = 4)
Age (years) 9.3 ± 2.1 7.9 ± 3.3
Body weight (kg) 39.3 ± 8.9 36.6 ± 4.5
Gender (male/female) 2/2 3/1
VPCs/24 hours 12.75 ± 15.39 2748 ± 4842*
LVEDV (ml/m2) 67.68 ± 11.60 120.30 ± 3.85*
LVESV (ml/m2) 33.63 ± 7.45 72.50 ± 2.85*
EF (%) 49.83 ± 6.37 39.67 ± 3.68*
Urea (mmol/l) 6.00 ± 0.68 4.80 ± 1.22
Creatinine (μmol/l) 62.25 ± 6.40 65.00 ± 6.58
cTnI (ng/ml) ≤ 0.20 0.36 ± 0.04*
total RNA (ng/μl) 3.63 ± 0.33 4.23 ± 1.23
Age, body weight, VPCs, LVEDV, LVESV, EF, urea, creatinine, cTnI and total RNA
values in mean ± SD. cTnI ≤ 0.2 representing values under the detectable
limit. DCM: Dilated cardiomyopathy; VPCs/24 hours: ventricular premature
complexes in 24 hours; LVEDV: left ventricular end-diastolic volume; LVESV: left
ventricular end-systolic volume; EF: left ventricular ejection fraction; cTnI:
cardiac troponin I; RNA: Ribonucleic acid. * p < 0.05 vs control.
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potential diagnostic and prognostic biomarkers in car-
diovascular disease. Cardiac hypertrophy, myocardial in-
farction and heart failure were associated with different
expression profiles of circulating miRNA [25,31,53-58].
Several studies have also reported the potential of circu-
lating miRNAs as diagnostic, prognostic and therapeutic
marker for cardiovascular pathologies like coronary ar-
tery disease, stroke, diabetes mellitus or hypertension
[55]. With the exception of one study in humans investi-
gating miRNA expression in peripheral blood cells in
chronic heart failure caused by different cardiomyopa-
thies (including DCM [52]), studies about circulating
miRNA expression patterns in human DCM do not exist
to date.
Because of the increasing interest in canine genetics
and the benefits of using the domestic dog as a model
for human hereditary diseases, investigations on canine
miRNAs were initiated [59-64]. In 2007, a search of
genetic databases revealed significant conservation of
miRNA genes between the domestic dog and the human.
Expression levels of seven miRNAs were analyzed in sev-
eral canine tissues. This was the first study that success-
fully used quantitative Real-Time RT-PCR (qPCR) assays
originally designed for human miRNA detection and
showed full conservation of mature sequences of canine
and human miRNAs [61]. In 2008, Zhou et al. identified
357 miRNA candidates from the dog genome, 300 of
which were orthologous to already characterized human
miRNAs [60]. Deregulation of miRNA expression pat-
terns has been reported in various canine neoplastic tis-
sues and muscular dystrophy [59,62-64].
To our knowledge this is the first study about circulat-
ing miRNAs in canine DCM. The aim of this study was
to investigate whether Doberman Pinschers with DCM
and healthy controls display different serum miRNA ex-
pression patterns in order to evaluate a possible use of
miRNAs as biomarkers in dogs.
Results
Patient characteristics
Eight Doberman Pinschers with a mean age of 8.6 years
were included in the study and assigned to a DCM (n = 4)
and a control group (n = 4). Analysis using the Mann–
Whitney test revealed statistically significant differences
between the two groups for the parameters ‘ventricular
premature contractions’ (VPCs) and ‘left ventricular end-
diastolic volume’ (LVEDV), ‘left ventricular end-systolic
volume’ (LVESV, p = 0.0143) and ‘ejection fraction’ (EF,
p = 0.0286; Table 1).
Sample characteristics
None of the dogs had evidence of renal disease with urea
and creatinine values in reference ranges. Serum sampleswere stored at – 80°C for 240 ± 144 days (mean ± SD)
prior to analysis. Circulating cardiac troponin I (cTnI)
levels showed significant difference between the two
groups. Total RNA amounts of the serum samples used
did not differ between the two groups (for further base-
line characteristics see Table 1).
miRNA microarray
By employing a highly sensitive and custom-designed
8x60k miRNA microarray (Agilent Technologies, Santa
Clara, CA, USA), miRNA expression profiles of canine
serum were determined. After subtracting background sig-
nals, a total of 404 individual miRNAs could be detected.
One sample of the DCM group was removed from fur-
ther miRNA microarray analysis because of inconsist-
ency of expression levels compared to other samples
(Figures 1 and 2).
Expression of 22 miRNAs was different between the
two groups (p < 0.05 and fold change (FC) > 1.5, moder-
ated t-test, Software “LIMMA”). Expression differences
of all miRNAs were relatively small and did not exceed a
2.3-fold change. miR-142-3p showed a 2.18-fold change
(p: 0.0042), miR-144* a 2.20-fold change (p: 0.0016),
miR-21 a 1.67-fold change (p: 0.0089) and let-7c was
negatively 1.53-fold changed (p: 0.0340). Adjusted p-
values of all 22 miRNAs after multiple testing correction
did not reach statistical significance (false discovery rate
adjusted p > 0.05; Table 2). miR-92a was different be-
tween the groups but marginally missed the inclusion
criteria for the definition of differential expression (cfa-
miR-92a: p: 0.0359; FC: - 1.45; mmu-miR-92a: p: 0.0422;
FC: - 1.41;). However, miR-92a was considered for fur-
ther analysis (see qPCR). Hierarchical cluster analysis
Figure 1 Matrix of pairwise correlations. Red coefficient of correlation = 1, blue = lowest values; 1A: Correlation matrix showing all samples.
Color intensity of DoCM8 is markedly different to other columns indicating strong differences of expression levels compared to other samples.
Strong blue colored boxes are illustrating much lower correlation compared to light colored boxes of the other samples. 1B: Correlation matrix
after exclusion of DoCM8. All boxes are colored similarly indicating uniform variation between all samples. DoCM: DCM in Doberman Pinschers;
Con: Control.
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patterns between healthy and diseased dogs. This ana-
lysis revealed a clear separation of healthy and diseased
samples that was stable with 200 iterations as well as
relatively high variation within both groups (Figure 3).
qPCR
For further analysis, we selected five miRNAs which
have been earlier mentioned in literature as being
involved in cardiovascular pathology and which also
showed a trend for differential expression in the micro-
array (miR-142-3p, miR-144*, miR-21, let-7c and miR-
92a). Five target miRNAs and two endogenous controls
were measured by qPCR in the same serum samples
used previously for the microarray. The endogenous
controls hs_RNU6B_2 and hs_RNU1A_1 did not show a
difference in average Δ Δ threshold cycle (Ct) between
the groups (hs_RNU6B_2: 27.04 ± 0.62 vs 27.3 ± 0.75;
hs_RNU1A_1: 15.72 ± 0.57 vs 15.27 ± 0.94; mean ± SD).
miR-142-3p and miR-144* showed a trend of upregula-
tion in the diseased group, whereas let-7c was slightly
downregulated in DCM dogs. Differences between the
groups remained very small. Results showed a high inter-
individual variance of expression. While the miRNA
microarray showed small differences in expression of
miR-21 and miR-92a, qPCR revealed almost no differ-
ences of these miRNAs between the two groups (Figure 4).
With p-values > 0.05 for all tested target assays, qPCRrevealed no statistically significant difference between dis-
eased and healthy dogs (mmu-miR-142-3p: p = 0.771;
mmu-miR-144*: p = 0.421; cfa-let-7c: p = 0.634; cfa-miR-
21: p = 0.940; cfa-miR-92a: p = 0.873).
Discussion
To date, the role of miRNAs in human DCM has only
been studied using cardiac tissue samples [44,48,50,65,66].
These samples are difficult to obtain and studies on circu-
lating serum miRNAs present a much less invasive ap-
proach, although the origin and circumstances of miRNA
release into the circulation are currently unknown. Myo-
cardium specific miRNAs have been found to be signifi-
cantly increased in the serum as soon as one hour after
myocardial infarction in humans and mice [31,67]. The
spontaneous disease model of canine DCM in the
Doberman Pinschers may represent a useful target for
translational research. We limited the sample volume to
approximately 2 ml of whole blood to complete both
microarray and qPCR analysis, which can safely be
acquired even from small veterinary patients without
adverse effects.
According to manufacturer’s protocols, most micro-
array systems require a minimal amount of 100 ng total
RNA of each sample to be examined. We used in
average 117 ng (84–162 ng) total RNA per sample and
more than 400 miRNAs showed a sufficient intensity for
evaluation. However, higher RNA concentrations may
Figure 2 Whisker-Box Plot showing normalized data after
exclusion of DoCM8. Y-axis: vsn normalized signal intensities (log2
values). The bar near the middle of the box represents the median,
the bottom and the top of the box are representing the 25th and
the 75th percentile. Circles are displaying outliers. DoCM: DCM in
Doberman Pinschers. Con: Control.
Table 2 miRNAs with different expression in the miRNA
microarray analysis
miRNA FC p p adjusted
mmu-miR-1950 −2.14 0.0225 0.6331
mu-miR-744 −1.87 0.0117 0.5949
cfa-miR-30c −1.81 0.0141 0.5856
mmu-miR-5109 −1.75 0.0185 0.5903
mmu-miR-423-3p −1.74 0.0043 0.5558
mmu-miR-5115 −1.66 0.0110 0.5856
cfa-miR-376a −1.62 0.0141 0.5968
mmu-miR-1968 −1.58 0.0251 0.6331
cfa-miR-188 −1.57 0.0365 0.6405
mmu-miR-18a* −1.56 0.0159 0.6093
cfa-let-7c −1.53 0.0340 0.6331
mmu-miR-32 1.50 0.0476 0.6468
cfa-let-7f 1.53 0.0130 0.5968
mmu-miR-3104-3p 1.59 0.0226 0.6331
mmu-miR-5124 1.65 0.0468 0.6399
cfa-miR-21 1.67 0.0089 0.5856
cfa-miR-101 1.68 0.0402 0.6331
mmu-miR-101c 1.70 0.0394 0.6331
mmu-miR-5136 1.82 0.0409 0.6331
mmu-miR-144 2.02 0.0067 0.5640
mmu-miR-142-3p 2.18 0.0042 0.5640
mmu-miR-144* 2.20 0.0016 0.5476
p < 0.05, FC > 1.5; p adjusted with FDR. FC: fold change, FDR: false discovery
rate, cfa: canis familiaris, mmu: mus musculus, miR: microRNA.
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ard normalization for miRNA expression analysis of
serum samples using microarrays has not been estab-
lished so far, but normalization of serum volume is
reported to be the best method to determine quantity of
miRNAs in blood using qPCR [67]. Using the same
amount of total RNA in each sample could have pro-
duced less interindividual variation in microarray andPCR analysis and should be investigated in further
experiments.
We excluded one sample of the diseased group from
further analysis of microarray data since miRNA expres-
sion levels were extremely different to others even after
normalization. This sample was taken from a young dog
and had the longest storage time. Total RNA yield from
this sample was very low compared to the other samples,
whereas signals of miRNAs were intensified in this
sample. Patient age is described not to influence miRNA
levels in plasma [25] and miRNAs are claimed to be
robust against long freezing time [24,68]. Reasons for
the difference of this sample remain unexplained.
Since the miRNA database contains more murine and
human miRNAs than canine sequences we chose to use
both canine and murine targets for our microarray.
Sequences have been found to be highly conserved among
species with many mature miRNA sequences displaying
100% homology [36,61,63]. The microarray results confirm
that canine miRNAs hybridize with multiple murine tar-
gets, which facilitates studies using veterinary samples. The
phylogenetic relationship of mouse, dog and human is a
matter of debate and not unequivocally determined
Figure 3 Hierarchical cluster analysis (HCL support tree) summarizing miRNA expression differences. Each column represents 1 of 7
samples, each row represents 1 of 22 miRNAs with nominal p-values <0.05. Samples were reproducibly grouped in DoCM and controls after
unsupervised hierarchical clustering (MeV 4.7.1, Pearson correlation, HCL support tree, 200 iterations). The different colors of the tree visualize the
reliability of branching (black: 100%, grey: 90–100%, blue: 80–90%, green: 70–80%, yellow: 60–70%, ocher: 50–60%, magenta: 0–50%, red: 0%
support). Red and blue (rectangles) indicating higher and lower expression levels, respectively, relative to the mean of all samples (log2 mean-
centered expression values); DoCM: Dilated Cardiomyopathy in Doberman Pinschers; Con: Control; cfa: canis familiaris, mmu: mus musculus, miR:
microRNA.
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situation of noncoding DNA, some miRNA clusters have
been found to be unique to primates. In a pilot study we
tested mouse serum as positive controls for qPCR detec-
tion of several miRNAs vs canine serum and detected the
same PCR products in both samples using murine assays.Figure 4 Whisker-Box Plots showing expression ratios of miRNAs in t
healthy control and normalized to the control assays hs_RNU6B and hs_RN
the DCM group compared to the control group, while let-7c appears to be
interindividual variance of expression. Expression ratio of miR-92a and miR-
groups are evident. The dotted line in the box are representing the sample
and 75th percentile and the whiskers are displaying the outer 50% of obserNotably for miRNA studies of cardiac tissue, more infor-
mation is available for murine samples, including studies
on knockout mice. Additionally, a recent analysis of the
heart transcriptome shows a higher similarity between dog
and mouse than between dog and human [71]. As stated in
the manuscript it cannot be ruled out that some murinehe qPCR. Expression ratios in the diseased group were compared to
U1A. miR-142-3p and miR-144* were up regulated about two-fold in
slightly down regulated. The long whiskers represent the high
21 is nearly 1. No statistically significant differences between the
median, the bottom and the top of the box are representing the 25th
vations. miR: microRNA.
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this would also be the case for human probes. Whether
human or murine miRNAs as a whole are more closely
related to dog miRNAs and which one would be the ‘bet-
ter’ model so far remains an open question.
In our study, the differences in miRNA expression be-
tween the two groups were not large and consistent
enough to reach statistical significance when the results
were adjusted for multiple testing. Although single miR-
NAs were not statistically significant between the two
groups, hierarchical cluster analysis of several miRNAs
showed a clear separation of diseased and control sam-
ples and enabled a reliable differentiation between healthy
and diseased dogs. Therefore, a combined expression ana-
lysis of several miRNAs may be a new diagnostic tool for
the detection of DCM in Doberman Pinschers and should
be further investigated in future studies. This study with
its comparatively small patient cohort should be consid-
ered as a pilot study requiring confirmation and validation
of results in larger sample groups.
A microarray study comparing miRNA expression in
heart tissue samples from several human heart diseases
revealed let-7c to be significantly upregulated and miR-
101 to be significantly downregulated in human DCM,
although the changes were less than two-fold [48]. In
contrast, our study detected a downregulation of let-7c
and an upregulation of miR-101, but the changes were
quite subtle.
The let-7 family has been shown to be one of the most
abundant miRNAs in murine heart tissue [46]. Recently,
a decrease of myocardial let-7i was associated with se-
verity of left ventricular dysfunction and poor clinical
outcome in human DCM patients and therefore sup-
posed to be a potential prognostic marker [50]. Let-7i
was reported to target for toll-like receptor 4 (TLR4)
in vitro, a critical transcription factor in the myocardium
of DCM in humans [72,73]. In the presented study of ca-
nine DCM of Doberman Pinschers, expression changes
of let-7i were not evident, but it is not known to date
whether TLR4 is a critical transcription factor in canine
DCM.
miR-101 has been addressed in several studies as a po-
tent tumor suppressor and inhibitor of autophagy and is
obviously expressed in many different tissues [74,75]. A
specific regulating effect on the cardiovascular system
has not been detected to date.
miR-21 is universally expressed in various organs like
spleen, small intestine, colon and the heart [36]. Several
studies demonstrated the overexpression of miR-21 in
tumor tissues [76,77]. It is also highly expressed in
vascular smooth muscle cells, endothelial cells, cardio-
myocytes and cardiac fibroblasts [66,78-81]. Deregulated
expression of miR-21 has been described for proliferative
vascular disease, cardiac hypertrophy, heart failure andischemic heart disease [44,78,80,82-85]. Myocardial de-
generation with cardiac fibrosis and myointimal hyper-
plasia of the coronary vessels are common histologic
findings in the DCM of Doberman Pinschers [6,10,86,87].
miR-21 is upregulated during cardiac remodeling in re-
sponse to cardiac stress and leads to fibroblast prolifera-
tion and fibrosis in humans [66,88]. In the Doberman
Pinschers suffering from DCM, miR-21 appeared to be
slightly upregulated in the microarray, but the trend could
not be confirmed using qPCR assays. In human DCM
heart tissue samples, one study group found a subtle and
non-significant downregulation of miR-21 [48], while an-
other study claimed miR-21 to be significantly upregulated
about two-fold compared to healthy controls [50]. Re-
cently, experimental studies demonstrated an increase of
miR-21 expression in right ventricular cells induced by
drug therapy. Due to the increase of miR-21, right ven-
tricular function during right heart failure improved as
well [89].
In miRNA microarray, miR-92a was slightly downre-
gulated in DCM diseased Doberman Pinschers, but this
could not be confirmed using the qPCR assay. As men-
tioned above, a related miRNA, miR-92, was shown to
be downregulated in human DCM tissues [48,49]. Over-
expression of miR-92a inhibits angiogenesis in ischemic
myocardial tissues in mice and is involved in the control
of cardiomyocyte survival. Experiments of external in-
hibition of miR-92a led to improved left ventricular func-
tion [90]. Since all of the diseased dogs received positive
inotropic therapy (Pimobendan), this may influence miR-
92a expression. So far, very little is known about the
effects of cardiovascular therapy on miRNA expression.
For miR-142-3p and miR-144*, we found a trend for
upregulation in DCM diseased dogs both in the microar-
rays and the qPCR results, although interindividual vari-
ation was very high. miR-144 was also upregulated in
the microarray analysis. miR-144 and miR-144* are the
two strands of the double stranded precursor miRNA
(mir-144). miR-144 is known to be expressed in a cluster
with miR-451. The miR-144/451 promoter is activated
by GATA-4, a critical transcription factor in the heart.
Both partners of the cluster are supposed to confer pro-
tection against stimulated ischemia/reperfusion-induced
cardiomyocyte death and may therefore represent pos-
sible therapeutic agents for the treatment of ischemic
heart disease in humans [91]. The left ventricular dila-
tion, which is a characteristic sign of DCM, leads to
myocardial stress. The upregulation of miR-144 might
be a stress response of affected myocytes and an attempt
to protect the cells against this stimulus. Recruitment of
a larger canine patient cohort may allow further valid-
ation of these findings.
In accordance with our findings, miR-142-3p has been
shown previously to be upregulated in human patients
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[52]. This miRNA is one of five negatively regulating
cardiac hypertrophy in recent experimental models.
Therefore, miR-142-3p is currently discussed as a part of
potential therapeutic targets for the treatment of cardiac
hypertrophy [92].
The mechanism and exact circumstances of miRNA
release into the serum are not fully understood to date
[27]. Protected by protein-bound complexes or incorpo-
rated into lipid carriers, miRNAs are resistant to RNases
in circulation. It is estimated that about 80% of circulat-
ing miRNAs are secreted in protein complexes. The other
part of circulating miRNAs is released in membrane-
bound vesicles (apoptotic bodies, microvesicles, exo-
somes) [93-97]. It is suspected that the release of miRNAs
into the circulation occurs selectively and the existence of
a specific packaging mechanism is therefore suggested.
For example, in a metastatic gastric cancer cell line, mem-
bers of the let-7 family are selectively released into the cir-
culation [98]. Similarly, different human cell lines secrete
certain miRNAs upon serum deprivation as part of a
stress response [93]. The correlation between circulating
and tissue miRNA expressions is still controversial. Dis-
eased cells might not be the only origin of changes in
circulating miRNAs. It is also possible that currently un-
known signals, e.g. stress signals, are sent from the dis-
eased tissue to other organs in the body and cause a
specific release of miRNAs into the circulation. Several ex-
perimental studies have suggested that circulating miR-
NAs can be transferred to target cells and regulate gene
expression [99,100]. Circulating miRNA expression pat-
terns might therefore differ from expression patterns
extracted from the diseased organ itself. This could ex-
plain the discrepancies of circulating miRNA expression
patterns found in this study to cellular miRNA expression
patterns found in other studies.
All dogs in the DCM group received a background
therapy consisting of ACE-Inhibitors and Pimobendan
and either Sotalol or Amiodarone as antiarrhythmic
therapy. It is possible that medication did not only im-
prove cardiac abnormalities but also influenced miRNA
expression changes. The elevated cTnI levels of diseased
dogs in this study reflect ongoing myocardial injury.
Studies comparing circulating miRNA expression in dif-
ferent disease stages of DCM are needed to verify tem-
poral changes in the course of this disease. No studies
are published about a possible influence of the drugs
used to treat the dogs in this study on the miRNA
expression. For the purpose of this study only dogs with
unequivocal echocardiographic in addition to unequivo-
cal electrocardiographic changes were selected. There-
fore, only patients in advanced disease stages were
selected and it would have been unethical not to treat
those dogs. All dogs received the same backgroundtherapy (Pimobendan and ACE-inhibitors), but antiar-
rhythmic therapy was individualized [15,101]. Antiar-
rhythmic therapy was adjusted according to the patient’s
individual electrocardiographic changes and was there-
fore not completely homogenous. In some cases, antiar-
rhythmic therapy was changed in later visits (after
serum sampling) because of inadequate response to the
administered medication (change from Sotalol to Amio-
darone, combination of Amiodarone and Mexiletin or
combination of Sotalol and Mexiletin).
Conclusions
In conclusion, this study demonstrates that miRNA ex-
pression profiling is technically feasible in a clinical set-
ting, revealing its potential as a possible new diagnostic
approach in veterinary medicine. Standardized protocols
for normalization and larger group sizes for different
diseases are needed to confirm whether circulating miR-
NAs may serve as biomarkers in dogs in the future and
whether canine disease models display changes similar
to human heart diseases.
Methods
Ethic statement
The dogs in this study were examined during preventive
diagnostic procedures with the written consent of their
owners (to participate in a study in which remaining blood
samples not used for necessary diagnostic procedures are
stored and used for genetic, miRNA and other diagnostic
research procedures). All local regulations (Germany)
were strictly observed. The study was approved by the
University of Munich Committee on Research Ethics.
There is no permit number as this study is not based on
an invasive animal experiment. The data were obtained
during routine diagnostic procedures. As the data are
from client-owned dogs that underwent normal veterinary
exams, there was no "animal experiment" according to the
legal definitions in Germany. Nonetheless, the study was
reviewed and approved by the local ethics review boards.
Study population
Eight purebred Doberman Pinschers were retrospect-
ively selected from a large study cohort of the Ludwig-
Maximilians-Universität München (LMU Munich) with
a longitudinal study design starting in 2004. Each exam-
ination included a questionnaire completed by the
owner, recording of body weight, physical examination,
short-time electrocardiogram (ECG), Holter monitoring
and echocardiography. Echocardiography included M-
Mode and Simpson’s method of disc measurements as
well as color and spectral Doppler measurements. Ven-
ous blood was collected from each patient for screening
of serum parameters and the samples were stored for
further analysis with the owner’s consent. We included
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systemic disease. Exclusion criteria were evidence of
concomitant congenital heart diseases or mitral valvular
disease in echocardiography. We retrospectively chose
eight dogs which met selection criteria of groups as
defined below.
ECG
Dogs were positioned in right lateral recumbency. ECG
was performed according to standard technique with a
twelve channel ECG machine (Schiller Cardiovit AT-10,
SCHILLER Medizintechnik GmbH, Germany). Electrical
activity was recorded for about 30 seconds and printed
for evaluation of any electrical abnormalities. A concur-
rent ECG was recorded during echocardiography with-
out getting printed.
Echocardiography
Echocardiography was performed without sedation in
right and following left lateral positions. Examinations
were performed with a high frame rate ultrasound system
with 2.0/4.3 MHz probes and simultaneous ECG record-
ings (Vivid 7 dimension, General Electric Medical System,
Waukesha, WI). Simpson’s method of disc measurements
were recorded in right parasternal long-axis and left apical
four chamber views. All valves were examined by color
Doppler technique. Spectral Doppler was used for velocity
measurement over the aortic and pulmonic valves and
had to reveal no evidence of abnormalities.
Holter examinations
Holter monitoring was performed following echocardi-
ography. The electrical activity was recorded for 24
hours in the normal environment of the dogs without
clinical habitation. Monitor was removed after 24 hours
and commercially available Holter analysis systems were
used for analysis of the digitally recorded ECGs (Custo
tera, Arcon Systems GmbH, Starnberg, Germany; Amed-
tech ECGpro Holter software, EP 810 digital recorder,
Medizintechnik Aue GmbH, Aue, Germany). Manual
adjustments and verification of accuracy of systemically
detected arrhythmias were performed by veterinarians
with experience in Holter analysis. Total numbers of
VPCs were tabulated.
Blood preparation
Blood (5 ml) was drawn from jugular vein of each pa-
tient and allowed to clot at room temperature for at
least 20 minutes. The sample was centrifuged at 600 g
RCF for five minutes at room temperature and the
serum was transferred to 0.5 ml polypropylene tubes
(Eppendorf, Hamburg, Germany) and stored at - 80°C
until RNA isolation.Four dogs each were grouped into two different
groups according to the results of the electrocardio-
graphic and echocardiographic examination:
– Control group: Dogs in this group had an age of
seven years or older and no clinical signs of systemic
or cardiac disease. Renal parameters had to be in the
reference range (Urea: 3.3 – 8.3 mmol/l, Creatinine:
31.8 – 117 μmol/l) and cTnI levels had to be ≤ 0.2
ng/ml. There were no electrical abnormalities in the
ECG: all amplitudes, duration of PQ-interval and
mean electrical axis were in normal ranges, dogs had
< 50 VPCs in the Holter examination.
Echocardiographic measurements were considered
to be normal. This includes no or only trivial
insufficiencies of the valves. Simpson’s method of
disc was used for calculation of the left ventricular
end-diastolic (LVEDV) and end-systolic (LVESV)
volume normalized to the body surface area (BSA).
LVEDV/BSA ≤ 100 ml/m2 and LVESV/BSA ≤ 55
ml/m2 were considered as normal [102]. The ratio
of the left atrium to the aorta (LA/Ao) was 1.5 or
less. We are in frequent communication by phone
with all owners. We perform yearly screenings to
monitor healthy dogs and to detect even early
changes. All healthy dogs are alive and healthy at
the time of reviewing this paper. We already
performed follow-up evaluations in 2012 and could
not detect any evidence of DCM in these dogs.
– DCM group (occult stage): Dogs in this group had no
clinical signs of systemic disease. Owners did not
observe any events of syncope or exercise
intolerance. Clinical signs of cardiovascular
abnormalities (pale mucosal color, weak pulse, pulse
deficit or arrhythmic pulse, heart murmur) were
acceptable. Renal parameters had to be in reference
range and circulating cTnI levels were elevated
(> 0.2 ng/ml). Electrical and morphological
abnormalities existed in the current visit or in one of
the earlier visits (partly normal under therapy in the
current visit): Dogs had > 100 VPCs in the Holter
examination and echocardiographic changes
including LVEDV/BSA > 100 ml/m2 and LVESV/
BSA > 55 ml/m2 [102]. LA/Ao had to be 1.5 or less.
We performed frequent control examinations every
1 – 6 months to monitor development of disease.
After the diagnosis of DCM, we performed 4 – 6
follow-up examinations of dogs in this group. The
time course of electrocardiographic and
echocardiographic changes is listed in Table 3. Due
to the severe existing changes, all dogs received
therapy at the time of serum sampling. Dosing of
drugs was standardized. Further characteristics of
diseased dogs are listed in Table 4.
Table 3 Time course of electrocardiographic and echocardiographic changes of dogs with DCM starting from time of
diagnosis
Sample name Number of visits VPCs/24 hours Maximal velocity of VPCs (bpm) LVEDV (ml/m2) LVESV (ml/m2) EF (%)
DoCM 5 1st visit 254 240 119.20 65.80 44.67
2nd visit 107 203 94.60 56.70 40.08
3rd visit* 161 200 116.80 73.10 37.41
4th visit 199 214 110.90 62.40 43.72
DoCM 6 1st visit 13641 300 105.70 63.40 39.97
2nd visit 10355 319 124.20 79.40 36.06
3rd visit* 10005 300 122.50 68.40 44.21
4th visit 14 196 112.30 77.60 30.93
5th visit 22 230 132.50 78.20 41.01
6th visit 24 300 142.50 94.50 33.73
DoCM 7 1st visit 1940 230 112.70 72.90 35.31
2nd visit 2478 275 121.70 82.40 32.31
3rd visit 17 273 116.40 79.90 31.40
4th visit* 616 180 117.30 75.00 36.04
5th visit 3010 250 151.20 108.50 28.24
6th visit 135 300 143.70 123.30 14.19
DoCM 8 1st visit 302 300 116.00 72.30 37.68
2nd visit 9 265 109.90 59.80 45.62
3rd visit* 209 202 124.60 73.50 41.01
4th visit 7295 300 99.00 50.50 48.93
DCM: Dilated cardiomyopathy, DoCM: Dilated Cardiomyopathy in Doberman Pinschers, VPCs: Ventricular premature complexes, VPCs/24 hours: ventricular
premature complexes in 24 hours; bpm: beats per minute; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; EF: left
ventricular ejection fraction, *: visit of serum sampling for microRNA analysis.
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Total RNA was isolated using the miRNeasy Mini Kit
(QIAGEN, Valencia, CA, USA) according to the supple-
mentary protocol “Purification of total RNA, including
small RNAs, from serum or plasma using the miRNeasy
Mini Kit”. Briefly, 400 μl serum were mixed with 2 ml of
QIAzol Lysis Reagent and 400 μl Chloroform. The sam-
ple was centrifuged and the upper aqueous phase was
transferred to a collection tube and mixed with 975 μl
100% ethanol. The mixture was applied to RNeasy Mini
spin columns and purified according to the protocol.
Total RNA was eluted using 50 μl of RNAse free water.
RNA concentrations were determined using a NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA). Samples were stored at -80°C.
miRNA microarray
The miRNA Microarray System with miRNA Complete
Labeling and hybridization Kit (Agilent Technologies)
was used according to the manufacturer′s recom-
mended protocol. The Agilent microRNA Spike-In Kit
was used for in-process control to measure labeling and
hybridization efficiency. The RNA samples were dried
in a Vacuum Contractor (Bachofer Plumbing Heating &Air Conditioning, Salina, KA, USA) for one hour. All
samples were dephosphorylated by incubation with calf
intestinal phosphatase at 37°C in a heat block for 30
minutes and incubated in 100% DMSO at 100°C for
seven minutes for denaturation. All samples were la-
beled with pCp-Cy3 using T4 ligase by incubation at
16°C for two hours. Micro Bio-Spin 6 chromatography
columns (Bio-Rad Laboratories, Hercules, CA, USA)
were used for purification of the labeled RNA. After
drying the samples completely, samples were prepared
for hybridization by adding nuclease-free water, Hyb
Spike-In solution, 10X GE Blocking Agent and 2X
Hi-RPM Hybridization Buffer. Samples were hybridized
to a custom-designed 8x60k Agilent microarray. The
custom microarray covered all murine and canine
miRNAs from miRBASE version 17.0 [103] and con-
tained probes for 1386 individual miRNAs with each
miRNA covered by 40 different features. Hybridizations
were performed in hybridization chambers (Agilent) for
20 hours at 55°C and the slides were washed as
described in the protocol. Arrays were scanned at a
resolution of 2 μm using an Agilent G2505C Scanner.
The microarray data discussed in this publication have
been deposited in NCBIs Gene Expression Omnibus













until the time of serum
sampling
Outcome Age at the time
of death (years)





DoCM 6 7.5 7.8 119 Pimobendan, ACE Inhibitor,
Amiodarone
Sudden cardiac death 8.6












DoCM: Dilated Cardiomyopathy in Doberman Pinschers. ACE: Angiotensin Converting Enzyme. *: The medication was not consistently administered because of
incompliance of the owner.
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Microarray data analysis
Feature Extraction Software Version 10.7.3.1. was used
for grid alignment and data extraction. Signal intensities
for each feature were scanned and calculated by
subtracting the background. The flag “is well above
background” (WABG) produced by the Feature Extrac-
tion Software was used to filter signals above back-
ground noise. Features had to contain a minimum of
two WABG flags “1” in at least one of the experimental
groups (detectable in at least two samples of the control
or the DCM group) to be included in the further ana-
lysis. Mean signal intensities were calculated for each de-
tectable miRNA probe and subsequently normalized
between samples using the BioConductor package “vsn”
[104]. For quality control, normalized data were analyzed
with a heatmap based on pair-wise distances (BioCon-
ductor package geneplotter). Software „LIMMA“(Bio-
conductor) [105] was used for significance analysis
(function “decideTests”) and assessment of miRNA ex-
pression changes.
Quantitative real-time RT-PCR (qPCR)
After total RNA purification, reverse transcription was
performed using the miScript Reverse Transcription Kit
(Qiagen) according to manufacturer′s protocol. The
miScript SYBR Green PCR Kit (Qiagen) was used for
qPCR according to the manufacturer′s protocol. The
miScript Primer Assays cf_miR-92a_1, mm_miR-142-
3p_1, cf_let-7c_1, mm_miR_144*_1 and cf_miR-21_1
were used as target miRNAs. hs_RNU6B_2 and
hs_RNU1A_1 were used as endogenous control assays.
All samples were run as duplicates. To account for
spurious PCR amplification of contaminating genomic
DNA, a control containing total RNA without reverse
transcription was included. As negative controls, theamplification mixture of each assay was run without
adding the reverse transcribed RNA. Relative quantifica-
tion was carried out using the Δ Δ threshold cycle (Ct)
method with hs_RNU6B_2 and hs_RNU1A_1 as en-
dogenous controls. The TaqMan 7500 Real Time PCR
System (Applied Biosystems, Life Technologies Corpor-
ation, Carlsbald, CA, USA) was used for qPCR.
Statistical analysis
Study population
The software GraphPad Prism version 5.04 for Windows
(GraphPad Software, La Jolla, CA) was used for statis-
tical analysis of the cohort. Mann–Whitney one-way test
was used to calculate differences for all parameters in
Table 1.
miRNA microarray
A “moderated t-test” (Software “LIMMA”) was used for
statistical analysis of the mean miRNA expression differ-
ences in the miRNA microarray. Multiple testing correc-
tion was performed using the parameter “FDR” (false
discovery rate) in the function “decideTests” for adjust-
ment of p-values. A p-value < 0.05 was considered to be
statistically significant. FC was calculated (Software
“LIMMA”) and included into the assessment of expres-
sion ratios (FC at least 1.5-fold was considered to be sig-
nificant). Software program Multi Experiment Viewer
(MeV v.4.7.1) was used for hierarchical clustering of 22
different miRNAs using HCL support trees, Pearson cor-
relation and 200 iterations.
qPCR
Target assays were normalized to internal controls
hs_RNU6B_2 and hs_RNU1A_1 which had been found
to be suitable as controls in dog serum in a preliminary
test. The software “REST 2009” was used for analysis of
relative expression in PCR assays [106,107]. Mean values
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< 0.05 was considered to be statistically significant.
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